Frontera et al. interestingly, reported higher neurodegenerative markers (neurofilament light chain (NfL), ubiquitin carboxy-terminal hydrolase L1 (UCHL1), and glial fibrillary acidic protein (GFAP)) in COVID-19 patients when compared to non-COVID controls with AD or with mild cognitive impairment [122], implying a deteriorated prognosis for neurodegenerative disorders with COVID-19 infection. The gene discussed is GFAP; the disease is Cognitive impairment.